Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Moxifloxacin IP 400 mg + Mannitol IP 5.0% w/v Infusuion
Therapeutic Category
Antibacterials, Antibiotic, General and OTC medicines
Dosage Form
Injection
Packaging Type
vial
Packaging
100 ml
Price
₹418/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Moxolunic IV is a highly effective infusion containing Moxifloxacin, a broad-spectrum fluoroquinolone antibiotic. It is specifically designed for the treatment of serious bacterial infections where oral antibiotic therapy is insufficient or not feasible. Moxifloxacin works by targeting bacterial DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication, transcription, and repair. This dual mechanism ensures robust bacterial eradication, making it a reliable choice in clinical settings.
This infusion provides a convenient and potent intravenous delivery, ensuring rapid achievement of therapeutic levels in the bloodstream. Moxolunic IV is particularly beneficial in managing severe infections caused by susceptible bacterial strains, offering high efficacy and rapid symptom relief.
Common side effects include nausea, dizziness, diarrhea, or injection site reactions.
Moxolunic IV is used to treat severe bacterial infections, including pneumonia, skin, and intra-abdominal infections.
Use only under medical supervision and complete the prescribed course.
Store below 25°C, protected from light and moisture.
Composition : Tolperisone (150mg) + Paracetamol (325mg)
Composition : Thiocolchicoside (4mg) + Aceclofenac (100mg) + Paracetamol (325mg) Tablet
Composition : Tolperisone (150mg) + Diclofenac (50mg)
Composition : Tolperisone (450mg) + Diclofenac (100mg)
Composition : Trypsin I.P. 48mg + Bromelain B.P. 90mg + Rutoside Trihydrate B.P. 100mg + Diclofenac I.P. 50mg
Composition : Tamsulosin (0.4mg) + Dutasteride (0.5mg)
Composition : Silodosin (8mg) + Dutasteride (0.5mg)
Composition : Timolol (5mg) + Brimonidine (2mg) Eye Drop
Composition : Tobramycin (0.3% w/v) + Fluorometholone (0.1% w/v)
Composition : Tranexamic Acid (500mg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Moxifloxacin 400 mg Infusion is a broad-spectrum fluoroquinolone antibiotic infusion used for the treatment of serious bacterial infections, including respiratory tract infections, community-acquired pneumonia, skin and soft tissue infections, intra-abdominal infections, and other severe systemic infections. The infusion formulation is primarily used in hospital and critical care settings, making it a valuable product in the anti-infective and hospital care segment.
Medical distributors and wholesalers can benefit from consistent demand from hospitals, nursing homes, critical care units, and physicians. Intravenous antibiotics are essential components of infection management protocols and generate regular institutional purchases, bulk orders, and stable business opportunities.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities in anti-infective, critical care, and hospital infusion segments with monopoly rights, quality manufacturing standards, and reliable supply support for distributors and medical agencies.
Wholesalers and institutional suppliers benefit from high hospital utilization, growing infection management needs, and strong physician-driven demand, making it a high-value, prescription-driven, and stable pharmaceutical category when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in critical care and anti-infective products can contact Cafoli Lifecare to discuss product availability, pricing structure, and PCD pharma franchise opportunities in the hospital care and anti-infective segment.